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ABSTRACT 
 
Congestive Heart Failure (HF) is a chronic progressive cardiac disorder with high mortality rates 
and is the number one reason for hospital readmission in the United States. More than 5 million 
Americans live with HF with more than 900,000 new diagnoses annually. The likelihood of 
developing HF increases with age making it the most common primary diagnosis for patients 
over age 65. HF has a significant impact on quality of life, with depression being a common 
comorbid condition. Thoracic impedance monitoring has shown to reduce exacerbations and 
hospitalizations in patients with HF. This project evaluated the literature related to impedance 
monitoring in the management of HF. The projected outcome for this project is to demonstrate 
the state of evidence regarding the effect of impedance monitoring on 30 day hospital 
readmission rates.  
Keywords: impedance monitoring, heart failure, readmissions, costs, transitions theory, and 
quality of life 
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Evaluating Impedance Monitoring to Reduce Hospital Readmissions for Patients with 
Heart Failure with Reduced Ejection Fraction: An Integrative Review 
Heart Failure (HF) is a chronic progressive cardiac disorder with high mortality rates and is 
the most frequent reason for hospital readmission in the United States (U.S.) (Ivany & White, 
2013). More than 5 million Americans live with HF with more than 900,000 new diagnoses 
annually (CDC, 2016). The likelihood of developing HF increases with age making it the most 
common primary diagnosis for patients over age 65 (CDC, 2016). About half of all HF diagnoses 
are heart failure with reduced ejection fraction (HFrEF) (Savarese & Lund, 2017). Thoracic 
impedance monitoring is a tool that is used to identify and predict heart failure exacerbations and 
prevents hospital readmissions (Franchuk, 2017). On average, the fluid index of impedance 
monitoring starts to rise 14 days prior to symptom onset (Yu, et al., 2005). Impedance 
monitoring in patients with HFrEF is not considered the standard of care despite there being 
evidence to support its use. The current recommendation for impedance monitoring frequency is 
every 3-12 months (Wilkoff, et al., 2008).  This scholarly project sought to evaluate the state of 
evidence regarding more frequent impedance monitoring in patients with HFrEF at high-risk for 
hospital readmission who have an existing implanted cardiac device with impedance monitoring 
capability.  
Background 
 
HF is a chronic progressive cardiac disorder that is characterized by the reduced ability of the 
heart to pump and/or fill with blood, which results in inadequate cardiac output to meet the 
metabolic demands of the body (Savarese & Lund, 2017). HF has been recognized as a global 
pandemic and affects nearly 26 million people worldwide and nearly 6 million people in the U.S. 
(Savarese & Lund, 2017). The likelihood of developing HF increases with age making it the 
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most common primary diagnosis for patients over age 65 (CDC, 2016). Every year in the U.S. 
there are over 900,000 new cases of HF. Heart disease is the leading cause of HF (Savarese & 
Lund, 2017).  The prevalence of developing HF is projected to rise because of the ageing 
population which will likely result in increased hospitalization rates and health care costs 
(Savarese & Lund, 2017). Alternative treatment and therapies are needed (Savarese & Lund, 
2017). HF is classified into three subtypes according to left ventricular function: HFrEF, HF with 
preserved ejection fraction (HFpEF), and HF mid-range ejection fraction (HFmEF). The 
diagnostic criteria for HFrEF is left ventricular ejection fraction (LVEF) <35%. The diagnostic 
criteria for HFpEF is LVEF 55-65%. The diagnostic criterion for HFmEF is LVEF 40-55% 
(Nadruz, 2016). This scholarly project will be focusing on patients with HFrEF.   
Due to the chronic nature of HF, it is difficult to medically and self-manage. Additionally, 
there are a variety of etiologies that can result in HF with risk factors including heart disease, 
smoking, and hypertension (CDC, 2017). Diagnostics that are currently used to assist in 
identifying and monitoring HF include biomarkers such as the b-type natriuretic peptide, 
echocardiography, 12-lead electrocardiography, echocardiography, and radiography (Coller, 
Campbell, Krum, & Prior, 2013).  A combination of therapies and disciplines is needed to 
provide optimal care. Patient participation and understanding is critical to positive outcomes 
(Riley & Masters, 2016). Lifestyle changes that often need to be made include a low sodium diet, 
fluid restrictions, and daily weight monitoring (AHA, 2017). Patients are often prescribed up to 
five medications, which are considered guideline-directed medical therapy. These medications 
include a diuretic, selected beta-blockade, ace-inhibitor, aldosterone antagonist, and sometimes 
digoxin (AHA, 2017). Many HF patients have a history of other cardiac illness such as 
myocardial infarction, hypertension, and arrhythmia. The diagnosis of HF can be very difficult 
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for patients to cope with and depression is a common comorbid condition. Nearly one in five 
patients with HF also have a diagnosis of depression (Mbakwem, Aina, & Amadi, 2016). A 
diagnosis of HF directly impacts a patient’s quality of life and is a major transition in a patient’s 
life. Hospital admissions and readmissions can be indirectly related to quality of life, so 
improvement processes around readmission reduction are multifocal to reduce costs and improve 
quality of life.  
One of the major reasons why there is so much emphasis on reduction of readmissions is 
because patients with HF who suffer from a 30 day readmission have a worse prognosis (Tung, 
et al., 2016). This underscores the importance of reducing readmissions as a means to improve 
HF outcomes (Tung, et al., 2016). Early identification of acute decompensated HF (ADHF) 
allows for early intervention and management. Methods for managing patients on an outpatient 
basis are continuing to be explored for patients with HF. Intravenous diuretic therapy is used as a 
more aggressive outpatient treatment option (Buckley, et al., 2016). Ideally, identification of 
ADHF happens early and treatment can be started quickly in the outpatient environment, 
preventing a readmission (Buckley, et al., 2016). Impedance monitoring is a way to identify 
patients who need early intervention for HF. Other interventions that can be implemented early 
for patients with HF include quality of life assessment, patient education on self-care behaviors, 
and referral to transitional care programs, such as home health care (Feltner, et al., 2014).  
Patients with HF undergo altered quality of life due to serious physical limitations and 
decreases in functional capacity (Marques de Sousa, dos Santos Oliveira, Oliveira Soares, 
Amorim de Araújo, & dos Santos Oliveira, 2017). Awareness of a patient’s thoracic impedance 
can enable clinicians to monitor quality of life in their patient population in addition to treatment 
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options. The Minnesota Living with Heart Failure Questionnaire (MLWHF) is the most widely 
used quality of life assessment tool for patients with HF (Marques de Sousa, et al., 2017). 
Patient education, with self-care being critical to positive outcomes, is also an integral part of 
HF management. Low sodium diets (He & MacGregor, 2011), monitoring of daily weights, 
medication adherence, fluid intake, and exercise are just a few of the self-care techniques that are 
taught to patients with HF (AHA, 2014). Management of symptoms through a low sodium diet is 
a finding that has been consistent in a large number of studies and He & MacGregor (2011) 
conducted a meta-analysis of outcomes trials to confirm this finding. This study’s purpose was to 
highlight that a behavior can reduce cardiovascular risk and it’s primary objective was to review 
the importance of reducing salt intake on cardiovascular health. The World Health Organization 
(WHO) supports this consensus and salt reduction is one of the top three priorities to tackle the 
non-communicable disease crisis (He & MacGregor, 2011). Reduction of salt intake is one of the 
primary education points in symptom management for patients with heart failure (CDC, 2016).  
Another component to care transitions is the utilization of home health services. HF patients 
that are discharged to a home health care service and who have early physician follow-up have 
been shown to have a reduced readmission rate (Murtaugh, et al., 2017). Additionally, patients 
with HF who received interventions based on their thoracic impedance monitoring combined 
with home health care had fewer 30 day readmissions than patients who only received home care 
(Shapiro, et al., 2017).  
Because HF is increasing in prevalence and is associated with high mortality and morbidity 
there is significant associated personal and societal burden. Functional decline and increasing 
dependence on others mark the transition for a more palliative approach with goals of care 
around quality of life and symptom management. Patients and caregivers recognize that heart 
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failure is a series of transitions (Jones, Nowels, Sudore, Ahluwalia, &Bekelman, 2015). 
Transition theory has been identified as an applicable nursing theory that offers hope during this 
time of transition. This theory helps clinicians, patients, and families adjust to the challenges of a 
diagnosis of HF and navigate the illness trajectory. Maintaining Hope in Transition is a 
theoretical framework stemming from Transitions Theory and is useful in the care of patients 
with HF. Key factors described include acknowledging circumstances, restructuring reality, 
dealing with vulnerability, achieving normalization, and resolving uncertainty. Incorporating 
theory into the plan of care can help assist clinicians and providers with care planning and 
focused interventions for patients and families from diagnosis to advanced stages (Davidson, 
Dracup, Phillips, Padilla, & Daly, 2007). It is important to consider each care option that is 
available to a patient.  
Palliative care is another important option to consider in the management of heart failure. 
Many clinicians are still learning the palliative care needs of their patients. This integrative 
review includes this topic in the discussion because of the focus on transitions of care. 
Impedance monitoring can be utilized to help clinicians manage HF and may guide the treatment 
plan even towards palliative care in the event that advanced therapies are not options and HF has 
negatively impacted the quality of life of the patient and their family (Ivany & White, 2013). 
This poor prognostic diagnosis encourages the need to continue to study ways to improve 
outcomes for patients with HF. Despite the chronic and progressive nature of HF there are 
barriers to providing palliative care. It is challenging dealing with the diagnosis of heart failure, 
and many patients are alarmed by the term palliative care (Ivany & White, 2013).  
Some patients with HF have been implanted with cardio-defibrillators (ICD) or cardiac 
resynchronization therapy with cardio-defibrillator (CRT-D) devices. For nearly 10 years experts 
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have been recommending the use of pacemaker technology in the management of cardiac 
patients (Toogood, 2007).  It is estimated that over 3 million Americans have a pacemaker, and 
nearly 600,000 pacemakers are implanted annually (Wood, & Ellenbogen, 2002). Thoracic 
impedance is a function of many pacemakers and ICD’s that are used today. ICD’s are indicated 
in patients with HFrEF with LVEF less than 35% and cardio-resynchronization therapy with 
defibrillator (CRT-D) are indicated for LVEF less than 35%, New York Heart Association 
(NYHA) class II-IV, normal sinus rhythm with the QRS greater than or equal to 150ms with a 
left bundle branch block pattern (Yancy, et al., 2017). The American College of Cardiology, 
American Heart Association, and Heart Rhythm Society Guidelines recommend that a 
pacemaker should be followed-up every 3-12 months, and those with ICD’s should be followed 
up every 3-6 months, with more frequent follow-ups as the battery approaches elective 
replacement (Wilkoff, et. al., 2008). While this is fairly frequent, this follow-up can occur 
remotely, termed remote monitoring, which can reduce the number of office visits a patient 
would need to make. In addition to battery monitoring, the pacemakers and ICD’s can monitor 
arrhythmias, and lung fluid accumulation, or impedance monitoring (Burri & Senouf, 2009). 
Thoracic impedance monitoring provides the clinician with fluid thresholds within the chest wall 
of patients and can alert the provider to threshold crossings that indicate fluid overload, or acute 
decompensated heart failure (ADHF) (Blair, 2014).  This review will demonstrate the state of 
evidence related to impedance monitoring on 30 day hospital readmission rates. 
Impedance monitoring is not currently a guideline recommended therapy, however, there are 
extensive randomized controlled trials and cohort studies that support its use (Blair, 2014; 
Shochat, et al., 2017; Miyoshi, et al., 2017). Impedance monitoring frequency varies in clinics 
across the U.S.; however, more frequent monitoring could provide an opportunity for earlier 
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intervention in those who are experiencing fluid overload and prevent 30 day hospital 
readmission (Coller, 2013). The national average for 30 day HF hospital readmissions is 21.6% 
in the U.S. (CMS, 2017). Many hospitals aim to achieve a readmission rate that is less than or 
equal to the national average for reimbursement purposes from Medicare (AHA, 2017).  
Problem Statement 
HF is a chronic progressive disease that results in physical, emotional, and financial 
burdens for individuals and healthcare systems (Ivany & White, 2013). On average, 50% of 
patients with HF who have a HF hospital admission will be readmitted within 6-months, and 
nearly 21.6% are readmitted within 30 days (CMS, 2017). Increased impedance monitoring is 
not a routine surveillance to predict HF exacerbations despite evidence demonstrating reduced 
HF exacerbations and hospitalizations (Tung, et al., 2016). This integrative review helps inform 
providers regarding the most recent and best evidence available in incorporating thoracic 
impedance monitoring for the care of patients with heart failure. An integrative review is 
valuable to providers because it reviews what is known about a subject, examines the quality of 
the information, determines what additional information should be known, and provides a 
recommendation for next steps in research and practice (Holly, Salmond, & Saimbert, 2017).  
Purpose & Significance of the Scholarly Project 
 
The purpose of this project is to evaluate the literature related to impedance monitoring in 
patients with HF on 30 day hospital readmissions and quality of life. The principle aim is to 
provide a synthesis of the evidence and make a recommendation to cardiovascular clinicians.  
Goals and Objectives 
• Objective 1: To provide an integrative review of the literature related to the effectiveness 
of remote impedance monitoring in reducing 30 day HF hospital readmissions. 
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• Objective 2: To provide a recommendation for remote impedance monitoring for 
outpatient management of HF. 
Clinical Questions 
This integrative review will address the following clinical questions:  
1. In patients with HFrEF who have an impedance monitoring device, does impedance 
monitoring reduce hospital 30 day readmission rates?  
2. In patients with HFrEF who have an impedance monitoring device, does impedance 
monitoring impact quality of life?  
Questions to support and maintain the focus of this review:  
1. Are there any studies that evaluate the effect of impedance monitoring on quality of life?   
2. Does increased impedance monitoring improve quality of life?  
3. Is there a nursing theory that can be applied to thoracic impedance monitoring and heart 
failure care?  
4. Does impedance monitoring identify early heart failure?  
5. Does impedance monitoring decrease readmissions?  
Methods 
Integrative Review Framework: Whittemore & Knalf 
The integrative review updated methodology by Whittemore and Knalf (2005) acted as 
the framework for this integrative review. This methodology distinguishes the integrative review 
from other review methods and allows for the combining of diverse methodologies, including 
empirical and theoretical, in the review (Whittemore & Knalf, 2005). Integrative reviews are the 
broadest type of research review and allow for the simultaneous inclusion of experimental and 
non-experimental research in order to fully encompass the information. This framework includes 
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the problem identification stage, data collection, literature search stage, data evaluation stage, 
data analysis stage, conclusion drawing and verification, and presentation stage. In addition to 
Whittemore and Knalf (2005), each manuscript was assigned a level of evidence (LOE) 
according to Melnyk’s system of hierarchy (Appendix A). In addition to the integrative review 
methodology, Transitions Theory acted as the theoretical framework and is discussed in detail in 
this section.  
Problem identification stage. The problem identification stage is the first step in the 
integrative review methodology. This stage is where a clear identification of the problem that the 
review is addressing occurs. This step provides focus and boundaries for the integrative review 
process (Whittemore & Knalf, 2005). This integrative review stems from the burden of heart 
failure on patients and healthcare systems. Its purpose is to analyze the literature related to a tool 
that can be used to manage heart failure and reduce the burden on both patients and healthcare 
systems. During the problem identification stage, data can be gathered from validated 
information sources to help guide the focus of the review. Hospital Compare’s, a national 
Medicare database, 30 day readmission rates were used to support this integrative review’s 
identified problem of higher readmission rates in patients with HF.  
Literature search stage. The next phase of the Whittemore & Knalf (2005) framework 
is the literature search stage. When performing an integrative review well defined search 
strategies are used to ensure there is a complete and unbiased search. The methodology of the 
literature search process is shared in the results section of this paper, including search terms, 
databases used, and inclusion and exclusion criteria for determining relevant primary sources. 
This integrative review’s search process was systematic in nature and included a discussion of 
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clinical guidelines, systematic reviews, clinical trials, cohort studies, literature reviews, and 
theory discussion.  
Data evaluation stage. The data evaluation stage reviews the types of studies included in 
the paper in order to evaluate the overall quality of the search. This includes identification of 
clinical guidelines, systematic reviews, clinical trials, cohort studies and whether or not the 
primary sources used a mixed method or qualitative research, versus a quantitative research 
method (Whittemore & Knalf, 2005). The quality of the studies for this review are organized in 
an evidence table using Melnyk’s hierarchy of evidence (Appendix A). The researcher also used 
specific selection criteria to help identify and structure the types of articles found.  
Data analysis stage. In the data analysis stage the data in research reviews are ordered, 
coded, categorized, and summarized into a unified and integrated conclusion about the research 
problem. This enables the researcher to organize the evidence in an unbiased manner and provide 
innovative synthesis of the evidence. This stage encompasses data reduction, data display, and 
data comparison (Whittemore & Knalf, 2005). The articles for this integrative review are 
organized and discussed in a hierarchical format based on the level of evidence.  
Data reduction. Data reduction is the determination of a classification system for 
managing data from diverse methodologies; for example, an integrative review includes 
information that is both qualitative and quantitative in nature. Primary sources are divided into 
subgroups according to some logical system to facilitate analysis (ex: qualitative/descriptive 
studies in one group). Sources can also be based on chronology, settings, and sample 
characteristics and are analyzed by topic. This organized technique enables the researcher to 
extract and code data into a manageable framework (Whittemore & Knalf, 2005). 
Predetermined/relevant data of each subgroup classification are extracted and complied into a 
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spreadsheet, which demonstrates succinct and organized literature, facilitating systematic 
comparison on issues, variables, and sample characteristics (Whittemore & Knalf, 2005). This 
integrative review utilized an evidence table organized into subgroups that classifies the level of 
evidence, type of study, and other characteristics.  
 Data display. Displaying data is a way to show how the data from multiple varying types 
of studies shares results. This can be done using graphs, tables, and charts (Whittemore & Knalf, 
2005).  This integrative review utilized tables and figures to help display the literature from 
varying types of studies.  
 Data comparison. Once data is organized and displayed the researcher can examine the 
displays for patterns, themes, or relationships. Concept mapping is another tool that can be used. 
Either tool used for data comparison helps to provide clarity for the empirical and/or theoretical 
components in the literature allowing support to emerge from early interpretive efforts 
(Whittemore & Knalf, 2005). This integrative review utilized an evidence table to organize the 
literature based on levels of evidence. The researcher found and displayed themes and 
commonalities in a flowchart.  
Conclusion drawing and verification. After the data is compared, the researcher can 
then draw conclusions by isolating patterns and processes as well as commonalities and 
differences in the literature. These conclusions must be verified with the primary source for 
accuracy. In the event of conflicting evidence, the need for further research with subsequent 
research questions aimed at resolving the conflict is recommended. Important elements and 
conclusions are synthesized and integrated into a summation. It is recommended that the entire 
process be documented so that thoughts, analytical hunches, and alternate hypotheses are 
incorporated as possibly relating to the interpretation of the data (Whittemore & Knalf, 2005). 
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This integrative review utilized the evidence table and flowcharts to help draw a conclusion 
regarding a recommendation for providers related to impedance monitoring in patients with heart 
failure.  
Presentation Stage. Lastly, the findings from the review are reported in explicit detail to 
provide a logical chain of evidence. Information that is already known is shared as well as the 
new information that the integrative review has added to the body of evidence and how it 
impacts or changes the existing general consensus (Whittemore & Knalf, 2005). This integrative 
review adds to the body of evidence by providing an extensive review of the literature and other 
concepts related to impedance monitoring and patients with HF.   
Theoretical Framework: Transitions Theory  
 This review has adopted a theoretical framework for support. A theoretical framework is 
helpful for the review because it can be used to define and guide variables and the relationships 
between the variables. A theoretical framework can help with evaluation of outcomes and 
providing directions for care (Smith & Liehr, 2014). Transitions Theory was used as the 
theoretical framework for this review. Transitions Theory offers a guideline and framework for 
the various transitions in a patient’s life. Also, this theory has an essential foundation within the 
nursing profession. A review of the literature was performed to identify supporting articles 
related to heart failure and Transitions Theory. Few articles were found and focused on palliative 
care, transitions prior to a cardiac procedure, and discharging from hospitals.  
Afaf I. Melieis developed Transitions Theory through research with immigrants and the 
transitions they face when they enter the U.S. (Meleis, 2010). The purpose of the theory is to 
describe, explain, and predict experiences of people in types of transitions including health and 
illness, situational, developmental, and organizational (Smith & Liehr, 2014). Key theory 
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concepts describe the types and patterns of transitions an individual may go through. These 
transitions span the lifetime, from birth to death. Additionally, this theory identifies properties of 
transition experiences, such as an illness from which the individual is suffering. Transition 
conditions, patterns of response, and process and outcomes indicators are also concepts described 
in the theory. Nursing therapeutics are embedded throughout each transition. There is also a 
relationship between the concepts as the individual moves through life. This theory has been a 
popular nursing theory because it can be used in nursing practices for people across unique 
health-related transitions (Smith & Liehr, 2014).  
Transitions Theory applies to patients with HF because they are they dealing with a 
serious health condition and learning how to manage this can be a difficult transition. The 
diagnosis itself is a transition and patients are sometimes faced with end-of life decisions. After 
diagnosis, there are markers of disease progression and transition, for example functional decline 
and increased dependence on others. This signals the need to transition their care to meet the 
patient’s needs (Davidson et al. 2007). Nurses, at all levels, play a central role in the lives of 
patients as they journey through life’s transitions. Nurses can aid in positive transitions by 
providing education, support, and/or direct care, thereby reducing disease and health risk. 
Additionally nurses enhance health and wellbeing and can assist those individuals as they move 
through transitions (Smith & Liehr, 2014). Impedance monitoring is a tool that can be used by 
clinicians and patients with HF to help them as they are dealing with their transition of managing 
a chronic disease (Blair, 2014). Patients with HF deal with a transition at diagnosis, from hospital 
to home, and throughout their disease process, which in many cases leads to subsequent 
admissions and end-of life. Transitions Theory will guide this review and careful attention will 
be paid to the transition from hospital to home and outpatient management.  
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Types and patterns. Transitions Theory has five concepts that will be related to this 
review. The first concept discusses the types and patterns of transitions an individual faces. 
During a lifetime an individual is faced with many transitions, including developmental, health 
and illness, situational, and organizational (Meleis, 2010). A diagnosis of HF is a major 
transition for an individual. Most people with this diagnosis are over the age of 65; however, 
older age does not make the adjustment easier. There are also individuals who are diagnosed 
with HF at a young age and undergo extensive treatment options such as a left-ventricular assist 
device and/or heart transplantation. A diagnosis of HF is characterized by a chronic progressive 
pattern of exacerbations and remissions evidenced by hospitalizations. This complex pattern is 
wearing on the patient, family members, and the healthcare team. This review acknowledges that 
a diagnosis of HF is a complex transition characterized by illness.  
Properties of the transition. The second concept reviewed by Meleis (2010) includes 
the properties of the transition experience. These properties include awareness of the transition, 
engagement, changes and differences, time span, and critical points and events that take place 
during the transitions. Meleis (2010) notes that awareness of change does not mean a person is 
ready for the transition and lack of awareness does not mean that the transition has not begun. 
This directly relates to a diagnosis of HF, because the heart’s ability to pump has already 
weakened before the patient is aware. Diagnosis is one of the most critical points during the 
disease process because the treatment plan is developed and prognosis is discussed. The time 
span of managing HF may last a few days, or may last years. It is critical to keep the patient and 
family members engaged and eager to participate in the care plan.  
Transition conditions & process/outcomes indicators. Transition conditions is the next 
concept in Transitions Theory. There are many conditions that influence the way a person moves 
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through a transition. Conditions can facilitate or inhibit the transition process and outcomes. 
These conditions may be personal or community and societal (Meleis, 2000). The family unit is a 
major condition that impacts how a person moves through a transition. The support, or lack of 
support, from a family member or caregiver can positively or negatively impact how a person 
moves through the diagnosis and management of HF. These conditions influence the next phase 
of the concepts, which include patterns of response-process and outcomes indicators. Process 
indicators lead the patient toward health or vulnerability and risk. Outcome indicators are used to 
determine if the transition is healthy or not (Meleis, 2000). This review seeks to identify positive 
conditions surrounding patients with HFrEF by evaluating impedance monitoring on 30 day 
hospital readmissions and quality of life.  
Nursing therapeutics. Lastly, nursing therapeutics is the final concept described by 
Meleis (2010) in Transitions Theory. Nurses are able to assess a patient’s readiness to accept the 
transition (Weis, et al., 2007). Nurses are part of a multidisciplinary effort and comprehensive 
treatment plan that seeks to help the patient and understand the needs of the patient. Nurses help 
prepare the patient through each stage of the transition and educate during critical points and 
events to promote the best outcome. Nurses also help people to understand the new role they 
may play as a result of their illness. These concepts are interrelated and adaptable, just as 
transitions flow and move over time. Transitions cause a change in identity, roles, relationships, 
and patterns of behavior. For example, children may have to become the caregiver for their 
elderly parent with HFrEF (Smith & Liehr, 2014).  
Christian worldview. Ecclesiastes is a book in the Bible written by King Solomon and 
inspired by God. He describes the transitions that occur in life. He wrote that there is a time to be 
born, and a time to die; a time to heal, and a time to break down. Looking at life from a Biblical 
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perspective gives meaning to life’s transitions. Solomon states there is a season and a time for 
everything under heaven. Jeremiah 29:11, is another Scripture passage that describes how God 
has a plan for each of us, and His plan is good. Applying the theory of transitions to this review 
as a theoretical framework incorporates the nursing perspective and its impact on patient care.  
Evaluation Methods 
This integrative review was evaluated by the author and chair on a continual basis to 
ensure that the evolving document upheld exactitude and met the requirements of the Doctor of 
Nursing Practice program at Liberty University. 
Search Strategy 
 The search strategy to identify the best evidence related to impedance monitoring to 
reduce readmissions for patients with heart failure with reduced ejection fraction (HFrEF) 
included a search of the Cochrane Library, CINAHL, and PUBMED. Keywords and phrases 
used for the search included impedance monitoring, heart failure, readmission rates, costs, and 
quality of life. Supporting questions were also used to help narrow the articles. No limits were 
placed on type of article or publication date. The search was limited to the English language and 
available free full text. These searches produced 196 hits. CINAHL produced 19 hits, Cochrane 
produced 74 hits, and PUBMED produced 103 hits.  
Study Identification  
 The researcher narrowed the search by publication date (2012-2017), study design, 
(clinical practice guideline, systematic review, controlled trial, cohort study, literature review, 
and theory) and available full text, which yielded 25 studies for review. Abstracts of the 25 
articles were reviewed for selection criteria. If any of the selection criteria were not indicated as 
a primary component, then the study was excluded from this systematic review. If the abstract 
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did not provide adequate information to determine selection criteria, the full text publication was 
reviewed. Studies that were appraised and included in identified systematic reviews were not 
individually appraised or discussed in this systematic review. A search of the National 
Guidelines Clearinghouse was conducted for professional guidelines pertaining to heart failure 
disease management to inform this review. After excluding articles that did not meet the 
selection criteria there were 14 articles included in this review and critical appraisal.  
Selection Criteria 
Population. The focus of this review was patients with HFrEF with impedance-
monitoring capability in their pacemaker device.  
Intervention. The intervention of interest was impedance monitoring in patients with 
HFrEF.  
Outcome. The principle outcomes of interest were hospital readmission rates, quality of 
life, and theory application.  
Study Design. Articles were included if they were classified as a clinical practice 
guideline, systematic review, controlled trial, cohort study, literature review, or theory 
discussion.    
Methods for Quality Assessment 
 A single reviewer critically appraised the quality of each manuscript. Clinical practice 
guidelines were appraised according to the Appraisal of Guidelines Research & Evaluation 
(AGREE, 2006). Each manuscript was assigned a level of evidence (LOE) according to 
Melnyk’s system of hierarchy (Appendix A).  
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Inclusion Exclusion 
Publications from 2012-2018 Publications prior to 2012 
Subjects greater than 18 years of age Subjects less than 18 years of age 
Study design Non research articles 
English language Language other than English 
Full-text articles Abstract only articles  
 
Table 1. Inclusion and Exclusion Criteria 
Critical Appraisal 
Clinical Practice Guidelines 
 The 2017 focused update guideline for the management of HF does not address 
impedance monitoring as a tool for the identification and management of HF (Yancy et al., 
2017). While this is not a current recommendation in the guidelines for HF and there is no 
mention of impedance monitoring in the report, the Heart Rhythm Society (HRS) and European 
Heart Rhythm Association (EHRA) have developed an expert consensus document in 
collaboration with the American Heart Failure Society and other professional organizations 
related to the techniques, indications, personnel, frequency, and ethical considerations of 
monitoring cardiovascular implantable electronic devices. This consensus mentions impedance 
monitoring in addition to rhythm monitoring, pacing, defibrillation, and battery monitoring 
(Wilkoff, 2008). It is recommended that a minimum frequency for in person or remote 
monitoring occur every 3-12 months, or more frequently if the device is a defibrillator. These 
recommendations are more extensive and discuss monitoring (battery, rhythm, leads, and 
thoracic impedance) from implantation through battery depletion. This document also discusses 
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the wide range of variety in the frequency of remote monitoring devices at a worldwide level and 
provided some basic recommendations for device monitoring. Disease-related monitoring, and 
specifically thoracic impedance monitoring as part of disease management in HF, is discussed as 
a goal for implantable devices (Wilkoff, 2008).   
Systematic Reviews 
 One systematic review was discovered that related to the study topic. Blair (2014) 
synthesized 24 randomized controlled trials that were performed to determine if device 
diagnostics could be used to identify HF exacerbations in the clinical setting. The purpose of this 
review was to determine if this early identification of HF can reduce hospitalizations with 
reduction of readmissions being its principle objective. The 24 studies were obtained using the 
databases of CINHAHL, MEDLINE, PubMed, and ClinicalTrials.gov. These studies were 
divided into two categories based on the primary objectives examined (Blair, 2014).  
First, the efficacy and prognostic value of device diagnostic data was evaluated and 
second the clinical feasibility of device diagnostic data and its impact on patient outcomes was 
evaluated.  This systematic review found that device data is capable of predicting HF 
exacerbations and also preventing hospitalizations. A strong correlation between cardiac 
biomarkers and hemodynamic measures was also discovered. The findings from this review 
indicate the ability for device diagnostics to assist clinicians to predict acute decompensated HF 
(ADHF) much earlier than other indicators, such as patient reported symptoms (Blair, 2014). The 
objective measures available with device diagnostics enables clinicians to be better informed and 
initiate communication with the patient rather than waiting for symptoms to be triggered. This 
allows for better clinical decision making because better and more accurate information is 
available to the clinician (Blair, 2014). This systematic review supports the importance of 
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utilizing device diagnostics to identify HF exacerbations and prevent hospitalizations. A study 
limitation that was shared by the author is that a bias exists towards Medtronic because the 
literature available on this topic was primarily from studies using Medtronic devices (Blair, 
2014).  
Clinical Trials 
 Multiple clinical trials have been performed to evaluate the impact of impedance 
monitoring on patients with HF and have shown a reduced rate of hospitalizations as well as 
increased survival. The lung impedance monitoring in treatment of chronic heart failure (LIMIT-
CHF) trial was an evidence-based European study published in 2016 and evaluated the impact of 
alerts on preventing HF hospitalizations for those patients who had device data and alert 
capability (Domenichini, et al., 2016).  The purpose of this trial was to evaluate the impact of 
alerts on preventing HF hospitalizations with the primary objective being to reduce readmissions. 
This was a randomized controlled trial and patients with chronic HF with OptiVol or CorVue 
capable implantable cardioverter-defibrillators were randomized to either the active group (IIM 
alarm turned on and diuretic dose increased by 50% for 1 week in the event of an alarm 
sounding) or the control group (alarm turned off). The primary endpoint of the trial was HF 
hospitalizations. Eighty patients were included in the study and divided into two groups: active 
group (41 patients) and control group (39 patients) however, 71 patients reached the one-year 
follow-up. There was a total of 11 HF hospitalizations in the active group vs. 6 in the control 
group without a significant difference in the number of episodes for each patient (Domenichini, 
et al., 2016). A decreased trend in MLWHF scores was found in the active group compared to an 
increased trend in the control group. This indicates an improved quality of life in the active 
group versus a reduced quality of life in the control group. While the study results did not show a 
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reduction in emergency HF treatment, there was a positive impact on quality of life.  A limitation 
shared is that there were a relatively high amount of IIM alerts that were not detected and 
consequently were not treated per the protocol. This may have reduced the potential benefit of 
alert guided treatment (Domenichini, et. al., 2016).  
The MOMOTARO (Monitoring and Management of OptiVol Alert to Reduce Heart 
Failure Hospitalizations) is a trial that was performed in Japan. This study’s purpose was to 
review a new algorithm that can be used to calculate impedance. The study’s objective was to 
reduce HF hospitalizations. The study consisted of 195 patients who had been implanted with a 
high-energy device and assessed the potential that fluid index could predict fluid accumulation 
and ADHF (Miyoshi, et al., 2017). The algorithm modification was then used to reduce the 
number of false-positive threshold crossings for HF and to more accurately diagnose actual fluid 
accumulation in patients at baseline and at an alert. During the study there were 154 primary HF 
events that were detected with the previous algorithm and there was no significant difference of 
the BNP between the baseline and alert. Using the modified algorithm, only 37 reached the 
threshold and the log BNP was significantly higher in these 37 events compared with the 
baseline value (Miyoshi, et al., 2017). This study supports the need to assess the fluid index in 
patients with devices and use it to assist in predicting fluid accumulation. Study strengths were 
that this was a randomized controlled trial with findings that support the study topic. Limitations 
include that this was a simulation rather than a prospective clinical study and raw data for 
patients with HF hospitalizations without threshold crossing events was not retained as a control 
and both would be recommended. Many factors can impact fluid retention in the chest wall 
including infection, pneumonia, and anemia and this new algorithm cannot detect between these 
other pathological conditions (Miyoshi, et al., 2017). 
IMPEDANCE MONITORING IN HEART FAILURE 32 
 The IMPEDANCE-HF trial was a randomized controlled trial that consisted of 256 
patients from 2 medical centers with chronic HF and ejection fraction (EF) <35% with New 
York Heart Association Class II-IV symptoms who were admitted for ADHF within 12 months. 
The purpose of this trial was to measure the degree of pulmonary congestion with non-invasive 
impedance and its objective was to reduce HF hospitalizations (Shochat, et al., 2016). The non-
invasive impedance monitoring means that it was not an implanted device, which is the 
traditional method for impedance monitoring. This new technology uses an electromagnetic field 
to externally measure thoracic impedance.  The 256 patients were randomized into the control 
group and the therapy group. The therapy group had noninvasive lung impedance measures 
performed monthly (every 30-days) and were followed for at least 12 months. Patients were 
blind to their assignment group. The primary endpoint was AHF hospitalizations and the 
secondary endpoint was all-cause hospitalizations and mortality. There were 67 (monitored 
group) v. 158 (control group) AHF hospitalizations during the first year, and 211 v. 386 AHF 
hospitalizations during the entire follow-up among the monitored patients (Shochat et al., 2016). 
During the follow-up there were 42 and 59 deaths, 13 and 31 resulting from HF. IMPEDANCE-
HF trial results showed that lung impedance guided treatment reduces hospitalizations for heart 
failure and decreases HF-related mortality. These results validate the concept that lung 
impedance preemptive treatment reduces hospitalizations and incidence of HF, as well as CV 
and all-cause mortality (Shochat et al., 2016). This study added tremendous evidence that early 
detection of hemodynamic changes enables clinicians to intervene early and in the outpatient 
environment (HFSA, 2016). The trial was extended to include a one-year follow-up sought to 
demonstrate the impact of impedance monitoring on survival (Shochat et al., 2016). This follow-
up was the first lung impedance trial that demonstrated this type of guided pre-emptive therapy 
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of worsening pulmonary congestion prevents HF hospitalizations, both HF and all-cause. This 
study also demonstrated that all-cause, cardiovascular and HF mortality was reduced. The study 
measured lung impedance with a new non-invasive high-sensitive device and supports the use of 
monthly impedance monitoring in patients with HF (Shochat et al., 2016). Strengths of the 
IMPEDANCE-HF study include that it offers cardiovascular clinicians insight into several 
clinical questions around the management of HF. First, it addresses that impedance monitoring 
can identify the degree of pulmonary congestion. Second, it addresses that pre-emptive 
monitoring, specifically every 30-days (more frequent than the current expert consensus 
recommendation) does reduce HF hospitalizations. Lastly, it addresses that impedance 
monitoring reduces all-cause and HF mortality. Limitations to this study include that the 
impedance monitoring device used was a new technological non-invasive tool, not specifically 
named in the study, and this technology is not as prevalent as traditional pacemaker impedance 
technologies. Also, this was a limited trial at one hospital site. A larger study across multiple 
centers would further clarify the benefits of impedance monitoring.  
Cohort Studies 
The researcher found multiple cohort studies in the literature that evaluated the use of 
impedance monitoring in the management of patients with HF. A prospective observational 
cohort study examined the correlation between pulmonary artery pressure and thoracic 
impedance and daily monitoring. The purpose of this study was to observe the impact of 
CardioMems, a small device implanted into the pulmonary artery, and measure pulmonary artery 
pressures (PAP) on thoracic impedance (Perego, et al., 2017). This was a study of 10 patients 
with HFrEF who had previously been implanted with an ICS capable of measuring thoracic 
impedance. Those patients were then implanted with CardioMems and both impedance and PAP 
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were remotely monitored daily. Investigators were blind to the PAPs for the first three months, 
then the PAP level was used to guide therapy. The study found that there is a direct correlation 
between left ventricle filling pressures and lung water content, however, there is a limited value 
in predicting episodes of thoracic impedance decrease (Perego et al., 2017). However, thoracic 
impedance decrease and PAP elevation precede ADHF. This study supports the need to perform 
impedance monitoring in patients who have the device capability. Study limitations include the 
small sample size and that the study participants were coincidentally all males, so gender related 
differences could not be excluded. Variations of thoracic impedance and PAPs were defined if 
they lasted greater than 7 days, so this definition may have influenced the study results (Perego 
et al., 2017). 
 The next study is a single-center prospective cohort study seeking to evaluate device 
monitoring in HF patients with a cardiac resynchronization therapy (CRT) device. Eighty 
patients were prospectively enrolled when they were implanted with biventricular defibrillators 
that had impedance monitoring capability (Forleo et al., 2013). Clinical heart failure status and 
impedance data were assessed during follow-up and if patients presented with an alert or heart 
failure deterioration. During follow-up there were 56 events of fluid index alerts identified in 29 
patients. Confirmed ADHF occurred in 23 out of the 29 patients. Confirmed ADHF resulted in 
14 hospitalizations and 7 of the 14 were preceded by an alert. False positives occurred in 23 of 
the 80 patients. False negatives are the primary study limitation with small sample size being 
another limitation. In summary, of the 56 fluid alerts, half were confirmed cases of heart failure. 
This study supports that impedance monitoring programs are feasible and can help to predict a 
HF exacerbation (Forleo et al., 2013). 
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 A subsequent cohort study sought to determine the effectiveness of impedance 
monitoring in heart failure patients with implanted cardiac defibrillators. The purpose of this 
study was to determine the effectiveness of impedance monitoring on heart failure and to assess 
patient’s perceptions of self-care. The researcher recruited 25 participants at a large private 
cardiology practice during an ICD interrogation if an impedance alert was triggered. After 30 
days a chart review was performed to assess if any intervention occurred in direct relation to the 
patient’s heart failure. The researcher administered the Self-Care of Heart Failure Index test as a 
pre and posttest to all patients to assess management, maintenance, and confidence in relation to 
their self-care habits (Franchuk, 2017).  Twenty-one study participants were male and 4 were 
female with the mean age of 69.5 years. The primary study result showed that patients 
confidence increased related to management of symptoms due to the surveillance of impedance 
monitoring. This article approached impedance monitoring from a different perspective and gave 
insight into how this type of device monitoring can influence patients’ abilities to perform self-
care. Study limitations shared by the author include that data collection only occurred at one 
office. Time constraint was also a study limitation because this study was performed during an 
academic year. Attrition rates were high for the phone recruitment resulting in a smaller sample 
size (Franchuk, 2017).  
 Shapiro, Bires, Waterstram-Rich, and Cline (2017) performed a retrospective chart 
review study to evaluate clinical outcomes for patients with class III heart failure. The study 
objective was that patients with Class III chronic HF who received interventions in the form of 
an implanted CorVue ICD and home health care would have fewer 30 day readmissions than 
patients who only received home care. The principle outcome of interest was to see if patients 
with CorVue ICD have lower 30-day readmission rates than patients without the device (Shapiro, 
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et al., 2017). One hundred and twenty patients were divided into a study group and a control 
group with 60 patients in each group. The researcher analyzed thirty-day readmission and 
mortality rates in each group. No patients with CorVue experienced a 30 day readmission. In 
contrast, 14 of 60 patients in the control group did experience a 30 day readmission (Shapiro, et 
al., 2017). This particular study had a 90 day time period with a small sample size therefore 
validity cannot be certain or results generalized.  More studies are needed to determine which 
interventions have the greatest financial impact as well as patient outcomes improvement 
(Shapiro, et al., 2017). 
The Detect Fluid Early from Intrathoracic Impedance Monitoring (DEFEAT-PE) is a 
prospective multicenter study that used impedance monitoring to detect pulmonary congestion 
(Heist et al., 2014). This study analyzed different intrathoracic vectors and their ability to predict 
ADHF. One hundred sixty-two patients were enrolled, 80 participants had ICDs and 82 had 
CRT-Ds. All participants had greater than or equal to one event of pulmonary congestion.  An 
alternative algorithm was used to detect pulmonary congestion and resulted in a sensitivity of 
21.6% and a false-positive rate of 0.9% per patient year. The DEFEAT-PE algorithms resulted in 
low sensitivity for the prediction of heart failure events; however, they were able to achieve an 
acceptably low false-positive rate. The Federal Drug Administration ultimately approved this 
algorithm.   
Results & Summary of Evidence  
In Patients with HFrEF Who Have an Impedance-monitoring Device, Does Impedance 
Monitoring Reduce Hospital 30 day Readmission Rates?  
While impedance monitoring is not a recommendation for care in the guidelines for 
patients with HF (Yancy et al. 2017), there is sufficient evidence in the literature that support its 
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use. The evidence supports that impedance monitoring identifies ADHF. Impedance monitoring 
can be a useful tool to predict fluid accumulation in patients with HF prior to symptom onset and 
can allow clinicians to intervene quickly with outpatient therapies (Franchuk, 2017). The studies 
provide evidence that its use can reduce hospital readmissions and mortality (Blair, 2014; 
Miyoshi et al., 2017; Shochat, et al. 2016). The literature supports that implementation of 
impedance monitoring programs in patients with HF can impact hospital readmissions and 
mortality rates. These outcomes are beneficial for patients and hospital networks as patient 
outcomes are often directly linked with financial incentives from insurance companies. A single 
systematic review, three clinical trials (IMPEDANCE-HF), and five cohort studies support the 
use of impedance monitoring to identify early ADHF (Blair, 2014; Domenichini et al., 2016; 
Miyoshi et al., 2017; Shochat et al., 2016; Shochat et al., 2016; Forleo et al., 2013; Heist et al., 
2014; Perego, et al., 2017; Franchuk, 2017; Shapiro, et al., 2017). 
Gaps identified include limited discussion on increased (more frequent than 3-12 month 
monitoring) and 30 day readmission rates. This researcher found one study that explored this 
supporting clinical question (Shochat et al., 2016) using a new technology. This study did find 
that 30 day monitoring reduces hospital readmissions (Shochat, et al., 2016). More studies are 
needed to support their study findings.  
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Figure 1. Impact of Impedance Monitoring on Readmissions. 
In Patients with HFrEF Who Have an Impedance-monitoring Device, Does Impedance 
Monitoring Impact Quality of Life?  
Impedance monitoring has the ability to impact the quality of life for patients with heart 
failure. The LIMIT-CHF Trial specifically analyzed quality of life in patients with HF who 
underwent impedance monitoring and reported that there was an improvement in quality of life 
(Domenichini e. al., 2016). The other clinical trials and cohort studies did not discuss quality of 
life as an outcome of interest.  
The HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable 
devices discussed that a goal of implanted cardiovascular devices with monitoring capability is 
to optimize quality of life; this encompasses thoracic impedance monitoring. However, no 
further discussion was provided on whether or not quality of life is an influencing factor on 
thoracic impedance recommendations (Wilkoff, 2008). Patients, however, expressed that this 
In patients with HFrEF who 
have an impedance-monitoring 
device, does increased 
impedance monitoring reduce 
hospital 30-day readmission 
rates? 
Does thoracic impedance 
monitoring identify early heart 
failure? 
Blair, 2014; Domenichini et. al., 
2016; Miyoshi et. al., 2017; 
Shochat et. al., 2016; Shochat et. 
al., 2016; Forleo et. al., 2013; 
Heist et. al., 2014; Perego, et. al., 
2017; Franchuk, 2017; Shapiro, et. 
al., 2017
Does increased impedance 
monitoring decrease 
readmissions? 
Blair, 2014; Miyoshi et. al., 
2017; Schochat, et. al. 2017
IMPEDANCE MONITORING IN HEART FAILURE 39 
type of monitoring helped them to identify positive behaviors and lifestyle modifications that can 
reduce cardiovascular risk (Franchuck, 2017; He & MacGregor, 2011).  
 
Figure 2. Impact of Impedance Monitoring on Quality of Life.  
Additional Analysis  
 A common theme throughout each article regardless of their study design was that there 
is a transition occurring in the patient’s health. This transition is marked by a heart failure 
diagnosis and/or hospitalized exacerbation and continues with discharge to home and 
management of the chronic illness. This theme led the reviewer to explore nursing theories 
around transitions and Transitions Theory was found to be very applicable to patients with heart 
failure.   
Limitations  
 Limitations shared in the literature included that there may be a bias towards Medtronic 
in the results of clinical trials because many clinical trials used Medtronic devices.  
Discussion 
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Implications for Research 
 Continued research is recommended to further solidify the use of impedance monitoring 
in the management of heart failure. This review highlights the current evidence related to 
impedance monitoring and early identification of HF, interventions used to manage HF, and 
impact on quality of life. More information is needed to see if more frequent impedance 
monitoring reduces 30 day hospital readmissions.  
Implications for Practice 
The significance of this review can greatly impact patients with HF and how they 
perceive their quality of life. The potential to predict a HF exacerbation enables the HF team to 
intervene prior to decompensation. Patients with HF often suffer from depression and struggle 
with the reality of living with a chronic disease (Herr et al., 2017). Quality of life is a major 
outcome in patients with HF and the ability to improve quality of life through impedance 
monitoring is impactful. At the micro level, or patient and clinician level, this can help to 
improve the patient and provider relationship. In addition to an improved relationship, the patient 
will have a better quality of life evidenced by a decrease in exacerbations requiring 
hospitalizations. At the organizational level, or the mesa level, the number of patients that are 
prevented from hospital admission can greatly impact the financial implications. Readmissions 
are costly for the patient and the organization because readmissions are associated with payment 
penalties. With a reduction in readmissions the penalties will decrease and enable the 
organization to save financially. Nationally this may help patients across the country that 
struggle with HF and as technology advances there may further innovations created enabling 
patients to review their threshold levels in real time and help them to make better decisions 
related to self-care (Forleo et al., 2013). 
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 The profession of nursing can utilize impedance monitoring as a patient education tool 
and as an assessment tool. Home health nurses and other nurses can utilize the data to help the 
patient identify when fluid is developing so that changes can be made in their lifestyle or 
medications (Shapiro, 2017). Nurses across the country are caring for patients with HF; nearly 
every nurse has encountered a patient with this diagnosis. This review and other scholarly 
projects help to elevate the profession of nursing amongst the healthcare community. Subsequent 
scholarly work related to impedance monitoring can continue as new technologies and devices 
are being developed.  
DNP Essentials  
Essential I: scientific underpinnings for practice  
The DNP Essentials highlight the preparation of the doctorate prepared nurse and the 
many avenues of healthcare that the nursing profession embodies. The first essential is the 
Scientific Underpinnings for Practice, which reflects the complexity of practice at the doctoral 
level and the rich heritage that is the conceptual foundation of nursing. This integrative review 
reflects this essential by integrating nursing science with knowledge that is biophysical, 
psychosocial, analytical, and organizational. This review used science-based theories and 
concepts to determine the nature and significance of health and health care delivery, described 
the actions and advanced strategies to enhance the care of heart failure patients, and evaluated 
the outcomes of the literature (AACN, 2017).  
Essential III: clinical scholarship and analytical methods for evidence-based 
practice 
This review reflects the hallmark of the doctoral education by providing a detailed 
analytical scholarship review related to the care of patients with HF. This review incorporates 
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this DNP Essential by investigating and synthesizing evidence across disciplines and types of 
research to help solve health care problems and improve health outcomes. This review used 
analytical methods to critically appraise the literature to inform providers and institutions 
regarding the use of impedance monitoring technologies in the care of patients with HF (AACN, 
2017). An integrative review appraises and combines available evidence, including theory and 
other information. This review method incorporates diverse methodologies to capture 
circumstances, processes, and individual elements of the topic under study (Whittemore & Knafl, 
2005). This type of review takes traditional review methods further and provides a broader focus 
(Holly, Salmond, & Saimbert, 2017) evidencing the exactitude of the DNP.  
Essential IV: information systems/technology and patient care technology for the 
improvement and transformation of health care 
This essential distinguishes the DNP graduate’s ability to use information systems and 
technology to support and improve patient care and healthcare systems and provide leadership 
within healthcare systems. This review assists providers in the use of information 
systems/technology to evaluate programs of care, outcomes of care and care systems. By 
performing this integrative review, healthcare providers will be better informed about the impact 
of thoracic impedance technologies on 30 day hospital readmissions and quality of life for 
patients with heart failure (ACCN, 2017).  
Conclusion 
In closing, managing patients with HF is a multidisciplinary effort with the patient being 
the most important member of the healthcare team. Diagnosis of HF is often a concerning 
diagnosis for patients and family members. HF it is very difficult to medically and self-manage 
and is characterized by exacerbations, and hospitalizations. Many patients with HF are on an 
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end-of-life trajectory, as HF is one of the nation’s leading causes of death. One way to help to 
manage symptoms and decrease hospitalizations is to utilize impedance-monitoring capabilities 
through device technology. This review adds to the body of evidence for cardiovascular 
clinicians, thus improving the health of those who suffer with HF. Not only can impedance 
monitoring be a tool to reduce readmissions, but it can also be a tool evaluate quality of life, the 
patient’s ability to perform self-care, and identify when end of life discussions may need to take 
place. Impedance monitoring can be a diverse tool for the management of this chronic and 
progressive disease. The updated methodology by Whittemore and Knalf (2005) and Transitions 
Theory strengthen this integrative review. This review also is in conjunction with the DNP 
Essentials and seeks to evidence the scholarship and evidence-based values of the DNP. By 
incorporating the findings from this review the hope is that cardiovascular clinicians are better 
empowered to manage HF and help patients with quality of life. 
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Appendix A 
Table 2. Evidence for Impedance Monitoring 
Name: Evaluating Impedance Monitoring on Readmissions for Patients with Heart Failure with 
Reduced Ejection Fraction (HFrEF) 
 
Clinical Question: In patients with HFrEF, who have an impedance monitoring device, does 
impedance monitoring reduce 30 day hospital readmission rates?  
 
Clinical Question: In patients with HFrEF who have an impedance-monitoring device, does 
impedance monitoring impact quality of life?  
 
Title/ 
Author/ 
(year) 
Study 
Purpose/ 
Objective 
(s) 
Design, 
Sampling 
Method, & 
Subjects 
LOE Intervention 
& Outcomes 
Results Study 
Strengths 
& 
Limitations 
1. 2007 
ACC/AHA/H
FSA focused 
update of the 
2013 
ACCF/AHA 
guideline for 
the 
management 
of heart 
failure. 
Yancy, 2017 
This 
document is 
an updated 
version of 
the 2013 HF 
guidelines 
Clinical 
Practice 
Guidelines 
Level 
I 
This 
document 
services as 
the most 
updated 
version of 
the clinical 
practice 
guidelines 
for HF 
management. 
The 
guidelines 
do not 
discuss 
impedance 
monitoring 
in any 
form at 
this time 
for 
manageme
nt of HF 
Strength: 
this is the 
highest-
level 
document 
and is 
considered 
the standard 
for 
clinicians in 
managing 
heart failure  
Limitation: 
Does not 
discuss 
impedance 
monitoring 
as an 
alternative 
modality to 
identificatio
n of HF 
2.  Device 
diagnostics 
and early 
identification 
of acute 
decompensat
The purpose 
of this 
article was 
to 
synthesize 
the 
Systematic 
Review of 24 
studies 
pertaining to 
device 
diagnostics 
Level 
I 
This article 
synthesized 
the 
randomized 
controlled 
trials 
Device 
diagnostics 
showed a 
strong 
correlation 
with 
Strengths: 
This study 
supports the 
importance 
of device 
diagnostics 
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ed heart 
failure: a 
systematic 
review 
Blair, T. 
(2014) 
literature 
and its 
principle 
objective 
was to 
determine if 
device 
diagnostics 
can identify 
HF 
exacerbatio
ns 
and impact 
on patient 
data. The 
articles that 
were 
reviewed 
were 
obtained 
using 
Cumulative 
Index to 
Nursing and 
Allied Health 
Literature, 
MEDLINE, 
PubMed and 
ClinicalTrials
.gov  
regarding the 
efficacy of 
device 
diagnostics 
and how they 
can identify 
heart failure 
exacerbation
s in the 
clinical 
setting 
established 
HF 
biomarkers 
and 
hemodyna
mic 
measures. 
This 
indicates 
that device 
diagnostic 
parameters 
predict 
impending 
HF much 
earlier 
than 
traditional 
methods of 
monitoring
.  
to identify 
HF 
exacerbatio
ns and 
prevent 
hospitalizati
ons. 
Limitations: 
More 
studies are 
needed to 
review the 
device 
diagnostics. 
Bias was 
noted 
towards 
Medtronic 
devices 
because the 
literature 
available on 
this topic 
was 
primarily 
from studies 
using 
Medtronic 
devices.  
3. Early 
identification 
of 
asymptomatic 
subjects at 
increased risk 
of heart 
failure and 
cardiovascula
r events: 
progress and 
future 
directions. 
Coller, J.M., 
Campbell, 
D.J., Krum, 
H., Prior, 
The purpose 
of this 
article is to 
review the 
current 
tools that 
are used to 
identify HF 
including 
biomarkers 
and EKG’s 
and device 
diagnostics. 
Its objective 
was to 
encourage 
an agreed 
This study 
was a 
systematic 
review of 
multiple 
studies.  
Level 
I 
This article 
discussed the 
need for a 
screening 
tool for 
patients with 
heart failure 
and 
specifically 
talked about 
biomarkers 
and the 
SCREEN-HF 
trial taking 
place in 
Australia. It 
also 
This 
article is 
helpful 
because it 
identified 
the 
continued 
need for 
screening 
and 
monitoring 
of patients 
with HF. 
Article 
conclusion
s were that 
early 
Strengths: 
The 
literature 
and most up 
to date 
studies were 
reviewed 
and 
reported in 
this 
systematic 
review.  
Limitations: 
This study 
was not able 
to identify a 
single 
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D.L. 
(2013) 
policy and 
screening 
tool to 
identify 
patients 
with HF.  
reviewed the 
current 
published 
evidence for 
screening 
and 
addressed 
barriers and 
recommendat
ions for 
future 
research 
interventio
n in 
asymptom
atic 
cardiac 
pathology 
can 
improve 
clinical 
outcomes 
in many 
situations.  
screening 
tool, but 
was able to 
encourage 
the need for 
continued 
research to 
identify a 
screening 
tool.  
4. The lung 
impedance 
monitoring in 
treatment of 
chronic heart 
failure (the 
LIMIT-CHF 
study). 
Domenichini
, G., 
Rahneva, T., 
Diab, I. G., 
Dhillon, O. 
S., 
Campbell, 
N. G., 
Finlay, M., 
& ...  
Finlay, M. 
C.  
(2016) 
The purpose 
of this trial 
was to 
evaluate the 
impact of 
alerts on 
preventing 
HF 
hospitalizati
ons. The 
objective 
was to 
reduce 
readmission
s.  
Randomized 
controlled 
trial. Chronic 
HF patients 
with OptiVol 
or CorVue 
capable 
implantable 
cardioverter-
defibrillators 
were 
randomized 
to either the 
active group 
(IIM alarm 
turned on and 
diuretic dose 
increased by 
50% for 1 
week in the 
event of 
alarm 
sounding) or 
the control 
group (alarm 
turned off). 
Primary 
endpoint was 
HF 
hospitalizatio
ns per patient 
at 1 year.   
Level 
II 
This study 
(LIMIT-
CHF) 
evaluated the 
use of alerts 
in guiding 
HF treatment 
and to 
prevent HF 
hospitalizatio
ns. This 
study did not 
reduce 
emergency 
HF treatment 
but did have 
an impact on 
quality of 
life. 
Results: 80 
patients 
included in 
the study, 
71 reached 
1 year 
follow-up. 
There was 
a total of 
11 HF 
hospitaliza
tions in the 
active 
group vs. 6 
in the 
control 
group 
without a 
significant 
difference 
in the 
number of 
episodes 
per patient. 
A 
decreased 
trend in 
MLWHF 
scores was 
found in 
the active 
group 
compared 
to an 
Strengths: 
This was a 
randomized 
controlled 
trial that did 
show an 
impact on 
impedance 
monitoring 
on quality 
of life 
Limitation: 
The main 
limitation is 
related to 
the 
relatively 
high 
number of 
IIM alerts 
not detected 
and 
consequentl
y not treated 
as per 
protocol. 
This may 
have 
reduced the 
potential 
benefit of 
alert guided 
treatment.  
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increase in 
the control 
group.  
5. Correlation 
between 
pulmonary 
artery 
pressure and 
thoracic 
impedance: 
Insights from 
daily 
monitoring 
through an 
implanted 
device in 
chronic heart 
failure.  
Perego GB, 
Oldani M, 
Pellegrini D, 
Brasca 
FMA, 
Malfatto G, 
Villani A, 
Brambilla R, 
Rella V, 
Parati G 
(2017) 
 
The purpose 
of this study 
was to 
observe the 
impact of 
cardiomems 
and 
measureme
nt of 
Pulmonary 
Artery 
Pressures 
(PAP) on 
thoracic 
impedance.  
Prospective 
Observationa
l 
Study/Cohort 
Study of 10 
patients with 
reduced 
ejection 
fraction, 
previously 
implanted 
with an ICS 
capable of 
measuring 
thoracic 
impedance. 
These 
patients were 
implanted 
with 
CardioMems 
and both 
impedance 
and 
Pulmonary 
artery 
pressures 
were 
remotely 
monitored 
daily. 
Investigators 
were blind to 
the 
pulmonary 
artery 
pressures for 
the first three 
months, then 
this level was 
used to guide 
therapy.  
Level 
II 
Results: 
Strict 
correlation 
between LV 
filling 
pressures and 
lung water 
content, 
however 
there is a 
limited value 
in predicting 
episodes of 
thoracic 
impedance 
decrease.  
This 
article 
supports 
the need to 
perform 
impedance 
monitoring 
in patients 
with heart 
failure to 
prevent 
exacerbati
ons.  
Strengths: 
Supports 
the concept 
that 
impedance 
monitoring 
can predict 
fluid 
overload in 
patients 
with heart 
failure.  
Limitations: 
The study 
population 
of 10 
patients 
may have 
been why 
the study 
was not able 
to see a 
significant 
ability to 
prevent 
exacerbatio
ns. Also, all 
of the study 
participants 
were males, 
so gender 
related 
differences 
cannot be 
excluded. 
Also, 
variations 
of thoracic 
impedance 
and 
pulmonary 
artery 
pressures 
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were 
defined if 
they lasted 
greater than 
7 days, but 
also may 
have 
influenced 
the study 
results.   
6. An 
improved 
algorithm 
calculated 
from 
intrathoracic 
impedance 
can precisely 
diagnose 
preclinical 
heart failure 
events: sub-
analysis of a 
multicenter 
MOMOTAR
O 
(Monitoring 
and 
Management 
of OptiVol 
Alert to 
Reduce Heart 
Failure 
Hospitalizatio
n) trial study 
Miyoshi A, 
Nishii N, 
Kubo M, 
Okamoto Y, 
Fujii S, 
Watanabe A, 
Okawa K, 
Kawamoto 
K, Morita H, 
Ito H 
(2017) 
This study 
purpose was 
to review a 
new 
algorithm 
that can be 
used to 
calculate 
impedance 
and its 
objective 
was to 
reduce HF 
hospitalizati
on 
Randomized 
Controlled 
Trial. Study 
consisted of 
195 patients 
who had been 
implanted 
with a high-
energy 
device.  
Level 
II 
MOMOTAR
O trial in 
Japan 
assessed the 
potential that 
fluid index 
could predict 
fluid 
accumulation
/HF and 
algorithm 
modification 
to reduce the 
number of 
false positive 
threshold-
crossings for 
HF and to 
accurately 
diagnose 
fluid 
accumulation 
in patients 
baseline and 
alert.  
Supports 
the need to 
assess the 
fluid index 
to predict 
accumulati
on of fluid. 
There 
were 154 
primary 
HF events 
that were 
detected 
with the 
previous 
algorithm 
(Optivol 
1.0), and 
no 
significant 
difference 
of the BNP 
between 
the 
baseline 
and alert. 
Using the 
modified 
algorithm, 
only 37 
reached 
the 
threshold 
and the log 
BNP was 
significantl
Strengths: 
Large 
randomized 
controlled 
trial in 
Japan and 
could 
represent a 
new way to 
detect 
impending 
HF with 
improved 
reliability 
compared to 
the previous 
Optivol 
Algorithm.   
Limitations: 
Several 
limitations 
of the study 
include that 
this is a 
simulation, 
and a 
prospective 
clinical 
study is 
required to 
conclude 
whether the 
modified 
algorithm 
reduces 
false-
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 y higher in 
these 37 
events 
compared 
with the 
baseline 
value. 
positives. 
Also, raw 
data for 
patients 
with HF 
hospitalizati
ons without 
threshold-
crossing 
events was 
not retained 
as a control. 
Lastly, 
many 
factors can 
impact fluid 
retention 
including 
infection, 
pneumonia 
and anemia 
and this 
algorithm 
cannot 
detect 
between 
these other 
pathological 
conditions.  
7. Non-
invasive lung 
IMPEDANC
E-Guided 
preemptive 
treatment in 
chronic heart 
failure 
patients: A 
randomized 
controlled 
trial  
Michael 
Kleiner 
Shochat M, 
Shotan A, 
Kazatsker 
This trial’s 
purpose was 
to measure 
the degree 
of 
pulmonary 
congestion 
with non-
invasive 
impedance 
and its 
objective 
was to 
reduce HF 
hospitalizati
ons.  
Randomized 
Controlled 
Trial. 256 
patients from 
2 medical 
centers with 
chronic HF 
and EF <35% 
in NYHA 
class II-IV 
who were 
admitted for 
AHF within 
12 months 
were 
recruited. 
Patients were 
Level 
II 
IMPEDANC
E-HF trial 
results show 
that lung 
impedance 
guided 
treatment 
reduces 
hospitalizatio
ns for heart 
failure and 
decreases 
HF-related 
mortality. 
RCT. There 
were 67 
(monitored 
This 
article 
supports 
impedance 
monitoring 
and 
determined 
that it is 
the key 
determinan
t of HF 
hospitaliza
tions.  
Strengths: 
This study 
supports the 
use of 
impedance 
monitoring 
and 
encourages 
continued 
research on 
non-
invasive 
technologie
s.  
Limitations: 
No 
limitations 
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M, Asif A, 
Kleiner I, 
Weinstein 
JM, Dahan 
I, Blondheim 
D, Meisel S 
(2017) 
randomized 
into the 
control and 
therapy 
group. The 
therapy 
group had 
noninvasive 
lung 
impedance 
measures 
performed 
and followed 
for at least 12 
months. 
Patients were 
blind to their 
assignment 
group. 
Primary 
endpoint was 
AHF 
hospitalizatio
ns and 
secondary 
endpoint was 
all-cause 
hospitalizatio
ns and 
mortality.  
group) v. 158 
(control 
group) AHF 
hospitalizatio
ns during the 
first year, 
and 211 v. 
386 AHF 
hospitalizatio
ns during the 
entire follow-
up among the 
monitored 
patients. 
During the 
follow-up 
there were 42 
and 59 
deaths. 13 
and 31 
resulting 
from HF. 
Results 
validate the 
concept that 
lung 
impedance 
preemptive 
treatment 
reduces 
hospitalizatio
ns and 
incidence of 
HF, as well 
as CV and 
all-cause 
mortality.  
were 
discussed. 
8. One year 
follow up 
after 
termination 
non-invasive 
lung 
impedance-
guided 
preemptive 
This one-
year follow 
up study 
was after 
the 
conclusion 
of the trial 
and 
demonstrate
Randomized 
Controlled 
Trial. This 
article 
reviews the 
same 
population as 
the above and 
is the 1 year 
Level 
II 
The 
IMPEDANC
E-HF trial is 
the first lung-
impedance 
trial 
demonstratin
g that this 
type of 
This trial 
was a 
follow-up 
to the 
monthly 
impedance 
monitoring 
program 
and 
Strengths: 
This trial is 
pivotal in 
managemen
t of HF 
because it 
supports the 
need for 
preventive 
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treatment in 
chronic heart 
failure 
patients: a 
randomized 
controlled 
trial 
(impedance-
HF trial) 
Shochat 
MK, Shotan 
A, Kazatsker 
M, Asif A, 
Dahan I, 
Kleiner I, 
Blondheim 
D, Weinstein 
JM, Meisel S 
(2017) 
d the impact 
of this 
monitoring 
on survival.  
follow-up.  guided pre-
emptive 
therapy of 
worsening 
pulmonary 
congestion 
prevents HF 
hospitalizatio
ns in HF, 
reduces all-
cause, CV, 
and HF 
mortality in 
these 
patients. 
Lung 
impedance 
was 
performed 
with a new 
noninvasive 
high-
sensitive 
device. 
supports 
the 
importance 
of monthly 
impedance 
monitoring
.  
monitoring. 
It also 
encourages 
continued 
research in 
this area of 
medicine.  
Limitations: 
No 
limitations 
were 
discussed. 
9. Analysis of 
different 
device-based 
intrathoracic 
impedance 
vectors for 
detection of 
heart failure 
events (from 
the Detect 
Fluid Early 
from  
Intrathoracic 
Impedance 
Monitoring 
Study).  
Heist, E. K., 
Herre, J. M., 
Binkley, P. 
F., Van 
Bakel, A. B., 
Porterfield, 
The purpose 
of this 
article was 
to evaluate 
algorithms 
used to 
detect 
pulmonary 
congestion 
and to 
achieve an 
acceptably 
low false-
positive 
rate.  
Prospective 
Multi-Center 
study of 
multiple 
intrathoracic 
impedance 
vectors to 
detect 
pulmonary 
congestion 
events 
Level 
III 
162 patients 
were 
enrolled, 80 
with ICDs 
and 82 with 
CRT-Ds all 
with greater 
than or equal 
to 1 
pulmonary 
congestion 
event.  
An 
alternative 
algorithm 
was used 
to detect 
pulmonary 
congestion 
and 
resulted in 
a 
sensitivity 
of 21.6% 
and a 
false-
positive 
rate of 
0.9% per 
patient 
year. The 
DEFEAT-
PE 
algorithms 
Strengths: 
compared to 
other cohort 
studies this 
study 
analyzed 
multiple 
intrathoraci
c 
impedance 
vectors 
from 
multiple 
centers 
Limitations: 
Relatively 
small 
sample size 
and 
inability to 
have a high 
sensitivity 
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J. G., 
Porterfield, 
L. M.,  
& ... Pavri, 
B. B. (2014).  
 
resulted in 
low 
sensitivity 
for the 
prediction 
of heart 
failure 
events and 
able to 
achieve an 
acceptably 
low false-
positive 
rate. This 
algorithm 
was 
ultimately 
approved 
by the 
USDA.   
for the 
prediction 
of HF 
events.  
10. 
Retrospective 
application of 
program to 
access and 
review 
trending  
information 
and evaluate 
correlation to 
symptoms in 
patients with 
heart failure 
criteria  
for the 
remote 
management 
of patients 
with cardiac 
resynchroniza
tion therapy.  
Brasca, F. 
A., 
Franzetti, J., 
Rella, V., 
Malfatto, G., 
The purpose 
of this 
article was 
to review 
retrospectiv
e data and 
evaluate the 
correlation 
between 
symptoms 
of HF and 
the ability 
to remotely 
manage HF 
symptoms.  
Retrospective 
Analysis. The 
PARTNERS 
HF trial was 
evaluated to 
see if the 
criteria to 
detect initial 
decompensati
ng in 
moderate HF 
patients was 
possible 
under remote 
monitoring.  
Level 
III 
The 
PARTNERS 
HF criteria 
was 
retrospectivel
y applied to 
1860 
transmissions 
from 104 
patients who 
were enrolled 
in the 
telemedicine 
after cardiac 
resynchronis
ation therapy 
program. The 
criteria were 
tested to 
predict acute 
decompensat
ion occurring 
the 15 days 
following a 
transmission.  
In 441 
cases, 
acute HF 
was 
diagnosed 
after the 
index 
transmissi
on. This 
means that 
PARTNE
RS HF 
criteria 
could 
identify 
HF 
patients 
who 
subsequent
ly 
developed 
acute 
decompens
ation and 
these 
results 
Strengths: 
This study 
showed 
how device 
data can be 
utilized to 
provide 
objective 
data to 
patient 
symptoms. 
Limitations: 
More 
research is 
needed to 
correlate 
device data 
with 
symptoms 
and the 
ability to 
treat HF 
exacerbatio
ns through 
remote 
managemen
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Brambilla, 
R., Facchini, 
M., & ... 
Perego, G. B.  
(2017) 
warrant 
prospectiv
e studies to 
be done 
applying 
these 
criteria to 
remote 
monitoring
.  
t.  
11.Thoracic 
impedance & 
pulmonary 
artery 
pressure 
monitoring in 
prevention of 
heart failure 
hospitalizatio
n. 
Volodarskiy, 
A., Nazeer, 
H., Rosen, 
L., Patel, A., 
Jermyn, R. 
(2017) 
remove* 
This study’s 
objective 
was to 
evaluate 
whether 
thoracic 
impedance 
and 
pulmonary 
artery 
pressure 
correlate 
and predict 
HF 
hospitalizati
ons.  
Cohort Study 
of 15 patients 
that were 
implanted 
with 
CardioMems 
at euvolemic 
states and a 
concurrent 
Medtronic 
Automatic 
Implantable 
Cardioverter-
Defibrillator 
with OptiVol 
sensore were 
recruited  
Level 
III  
Data was 
abstracted 
from the 
patient’s 
devices and 
charts were 
reviewed for 
hospitalizatio
ns for heart 
failure. An 
analysis was 
performed 
for an overall 
correlation 
between the 
two 
modalities as 
well as any 
changes in 
modality in 
the 14 days 
preceding the 
hospitalizatio
ns.  
Results: 
The 15 
patients 
were 
average 
age of 65.7 
years and 
predomina
tely male 
with an 
average 
EF of 
34%. 7 of 
the 15 
patients 
had 11 
hospitaliza
tions for 
HF. No 
significant 
changes in 
either the 
PA 
diastolic 
pressure or 
impedance 
were 
discovered
.  
Strengths: 
These 
outcomes in 
the small 
cohort study 
supported 
the use of 
device 
monitoring,  
Limitations: 
sample size 
was a 
limitation 
and it was 
not 
randomized.  
12. Device 
monitoring of 
heart failure 
in cardiac 
resynchroniza
tion  
therapy 
The purpose 
of this 
single-
center 
cohort study 
was to 
evaluate 
Prospective 
Cohort 
Study. 80 
patients were 
prospectively 
enrolled 
during 
Level 
IV 
This was a 
prospective 
study of 80 
HF patients 
that 
confirmed 
the feasibility 
Results: 
during 
follow-up 
56 events 
of fluid 
index 
alerts were 
Strengths: 
include the 
feasibility 
to 
implement a 
device 
monitoring 
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device 
recipients: a 
single-center 
experience 
with a novel 
multivector 
impedance 
monitoring 
system. 
Forleo, G. 
B., 
Panattoni, 
G., 
Schirripa, 
V., 
Papavasileio
u, L. P., 
Della Rocca, 
D. G., 
Politano, A.,  
& ... Romeo, 
F.  
(2013) 
device 
monitoring 
in CRT HF 
patients.  
implantation 
of 
biventricular 
defibrillators 
with 
multivector 
impedance 
monitoring 
capability.  
and clinical 
usefulness of 
an 
impedance 
monitoring 
system, 
however, 
recommende
d larger 
studies to be 
performed. 
The 80 
patients were 
prospectively 
enrolled also 
and clinical 
heart failure 
status and 
impedance 
data were 
assessed 
during 
follow-up 
and if 
patients 
presented 
with an alert 
or heart 
failure 
deterioration. 
identified 
in 29 
patients. 
Actual HF 
events 
occurred 
in 23 
patients 
(worsening 
signs and 
symptoms)
. False 
positives 
occurred 
in 23 of 
the 80 
patients. 
Decompen
sation 
resulted in 
13 
hospitaliza
tions and 7 
of the 13 
were 
preceded 
by an alert.   
system but 
recommend
ed that 
further 
studies be 
done. 
Limitations: 
false 
positives do 
occur.  
13. 
Determining 
the 
effectiveness 
of impedance 
monitoring in 
heart failure 
patients with 
implanted 
cardiac 
defibrillators. 
Franchuk, 
A. 
(2017) 
The purpose 
of this 
article was 
to 
determine 
the 
effectivenes
s of 
impedance 
monitoring 
on heart 
failure and 
to assess 
patient’s 
perceptions 
of self-care.   
Cohort Study 
of 25 patients 
Level 
IV  
A 
comprehensi
ve literature 
search was 
done using 
CINAHL 
plus full test, 
PubMed, and 
Google 
Scholar prior 
to the study. 
This study 
was 
performed at 
a large 
private 
21 study 
participant
s were 
male and 4 
were 
female 
with the 
mean age 
of 69.5. 
Study 
results 
showed 
that 
patient’s 
confidence 
increased 
Strengths: 
This article 
evaluated 
self-care 
and the 
impact 
device 
monitoring 
can have on 
helping 
patients to 
improve 
self-care 
methods.   
Limitations: 
Data 
IMPEDANCE MONITORING IN HEART FAILURE 64 
cardiology 
practice. 
Participants 
were 
recruited 
during a 
device 
interrogation 
of their ICD 
or over the 
phone if the 
impedance 
alert was 
triggered. 
After 30 days 
a chart 
review was 
performed to 
assess if any 
intervention 
occurred in 
direct 
relation to 
the patient’s 
heart failure. 
A pre and 
post test was 
also 
administered 
to all patients 
(SCHFI test).  
related to 
manageme
nt of 
symptoms 
due to the 
surveillanc
e of 
impedance 
monitoring
.  
collection 
only 
occurred at 
one office. 
Time 
constraint 
was also a 
study 
limitation 
because this 
study was 
performed 
during an 
academic 
year. 
Attrition 
rates were 
high for the 
phone 
recruitment 
resulting in 
a smaller 
sample size.  
 
14. 
Improving 
Clinical  
Outcomes for 
Patients with 
Class III 
Heart Failure.  
Shapiro, M., 
Bires, A. M., 
Waterstram-
Rich, K., & 
Cline, T. W. 
(2017) 
Study 
objective 
was that 
patients 
with Class 
III chronic 
HF who 
received 
intervention
s in the 
form of an 
implanted 
CorVue 
ICD and 
home health 
Retrospective 
Chart Review  
Level 
IV 
A 
retrospective 
chart review 
compared the 
30-day 
readmission 
rates and 
mortality 
rates. An 
analysis and 
comparison 
of 120 
patients. The 
patients were 
divided into 
Results: 
No 
patients 
with 
CorVue 
experience
d a 30-day 
readmissio
n. In 
contrast, 
14 of 60 
patients in 
the control 
group did 
experience 
Strengths: 
This 
supports the 
need to 
implement a 
device 
monitoring 
program. 
More 
studies are 
needed to 
determine 
with 
intervention
s have the 
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care would 
have fewer 
30-day 
readmission
s than 
patients 
who only 
received 
home care. 
Principle 
outcome of 
interest was 
to see if 
patients 
with 
CorVue 
ICD have 
lower 30-
day 
readmission 
rates than 
patients 
without the 
device.   
a control 
group and a 
study group 
with 60 
patients in 
each.   
a 30-day 
readmissio
n.  
greatest 
financial 
impact as 
well as 
patient 
outcomes 
improveme
nt. 
Limitations: 
Additional 
studies 
recommend
ed, the 
study time 
period was 
90 days 
with a small 
sample size 
therefore 
validity 
cannot be 
certain or 
generalized.   
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